← Back to home

Charcot-Marie-Tooth disease with sorbitol dehydrogenase deficiency (CMT-sord)

Clinical trials for Charcot-Marie-Tooth disease with sorbitol dehydrogenase deficiency (CMT-sord) explained in plain language.

Never miss a new study

Get alerted when new Charcot-Marie-Tooth disease with sorbitol dehydrogenase deficiency (CMT-sord) trials appear

Sign up with your email to follow new studies for Charcot-Marie-Tooth disease with sorbitol dehydrogenase deficiency (CMT-sord), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Promising drug for rare nerve disease trial pulled before start

Disease control Cancelled

This study was designed to test whether the drug govorestat could improve symptoms of Charcot-Marie-Tooth disease caused by sorbitol dehydrogenase deficiency (CMT-SORD), a rare nerve condition. It planned to enroll people aged 16 to 65 and compare govorestat to a placebo over 36 …

Matched conditions: CHARCOT-MARIE-TOOTH DISEASE WITH SORBITOL DEHYDROGENASE DEFICIENCY (CMT-SORD)

Phase 3 • Sponsor: Applied Therapeutics, Inc. • Aim: Disease control

Last updated Jun 27, 2026 13:00 UTC

Charcot-Marie-Tooth disease with sorbitol dehydrogenase deficiency (CMT-sord)

Get alerted when new Charcot-Marie-Tooth disease with sorbitol dehydrogenase deficiency (CMT-sord) trials appear

Promising drug for rare nerve disease trial pulled before start